Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients.
The effects of intravenous cisplatin (CDDP) administration on the generation of lymphokine-activated killer (LAK) activity in peripheral blood mononuclear (PBM) cells were investigated in cancer patients. The ability of PBM to generate LAK activity was significantly augmented 3, 5 and 7 days after a single dose, 50 mg m-2, of CDDP injection when compared to that before injection. NK activity of PBM was not altered. The distribution of lymphocyte subsets exhibited no significant change following CDDP injection, except CD2+ cells. However, the ability of monocytes in PBM to produce TNF-alpha was significantly enhanced 5 days after the drug administration, although IL-1-alpha and IL-1-beta production was not augmented.
Arinaga
S
S
Department of Surgery, Kyushu University, Beppu, Japan.
Adachi
M
M
Karimine
N
N
Inoue
H
H
Asoh
T
T
Ueo
H
H
Akiyoshi
T
T
D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D004067:Digestive System Neoplasms / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D002945:Cisplatin